HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
|Articles|October 1, 2008
- Psychiatric Times Vol 25 No 11
- Volume 25
- Issue 11
Broken Mug
Author(s)Richard M. Berlin, MD
Advertisement
By Richard M. Berlin, MD
Articles in this issue
about 18 years ago
Theoretical Models of Health Behaviorabout 18 years ago
The Differential Diagnosis of Childhood Developmental Disordersabout 18 years ago
Wrong Choicesabout 18 years ago
Coping With Obscene Phone Callsabout 18 years ago
Cyber Bullyingabout 18 years ago
The Dementias: Neuropsychiatric Syndromes of the 21st Centuryabout 18 years ago
Acupuncture: An Updateabout 18 years ago
Antipsychotics in Dementia: Evidence of Risk Mountsabout 18 years ago
Advances in Neuroimaging: Impact on Psychiatric PracticeAdvertisement
Related to this article
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
5